Gaspari Nutrition Novadex XT Review

Note on the name: the product is Novedex XT, not "Novadex XT". It is a post-cycle and "natural testosterone" supplement. The search results show it is not a nitric-oxide or pump product. Searching "novadex xt" on Amazon returned unrelated nitric-oxide products. Novedex XT was originally made by Gaspari Nutrition. It was marketed as a testosterone-support and anti-estrogen supplement for use on-cycle or post-cycle. Gaspari announced a voluntary national recall of all lots after the FDA said the product contains an aromatase inhibitor the agency does not consider a dietary ingredient. The ingredient was 3,17-keto-etiocholtriene, known as ATD. Later versions have been sold by Hi-Tech Pharmaceuticals. Retailers describe the reformulation as containing 3b-hydroxy-androsta-1,4,6-triene-17-one, 3b-hydroxy-androsta-4,6-diene-17-one and androsta-3,5-diene-7,17-dione. I could not verify exact current label doses, so none are given here. Mechanism: the product works by inhibiting aromatase. Aromatase is the enzyme that converts testosterone into estradiol. Retailer copy says these ingredients inhibit aromatase and so increase testosterone production. The ingredients and how they act: - **Androsta-1,4,6-triene-17-one (ATD-type compound):** The marketing describes it as an inhibitor that permanently binds to the aromatase enzyme, creating an irreversible reaction that reduces estrogen production and raises testosterone levels. That is "suicide inhibition". The enzyme is disabled, so it must be re-synthesised before estrogen conversion resumes. - **Long half-life:** The original formula used an ether or ester attachment. Marketing says this gives a longer half-life, so it can be taken once daily. - **Metabolite activity:** The same retailer says a metabolite, 4,6-testosterone, also binds the androgen receptor. - **Non-androgenic design:** The original copy also claimed the formula did not suppress the hypothalamic-pituitary-testicular axis. The intended outcome is less estrogen, so less estrogen-related water retention and gynecomastia risk. Users also hope for better testosterone-to-estrogen balance, muscle retention, a drier look and a better libido. These are manufacturer and retailer claims. Retailer copy for the older formula said no adverse events had been seen in pilot studies. The reviewer at Diets in Review said they had no access to clinical study results. Safety and regulatory points: The FDA noted possible adverse events with anti-aromatases, including infertility, adrenal insufficiency, and kidney and liver dysfunction. The agency concluded such products are likely to harm at-risk consumers. That group includes people with liver, kidney, adrenal or prostate concerns. Aromatase inhibitors act on the hormone system. People who are under 18, pregnant, have a medical condition, or are subject to drug testing should avoid them.